, Volume 17, Issue 3, pp 198–212 | Cite as

Drug Prescribing in Hepatobiliary Disease

  • R. K. Roberts
  • P. V. Desmond
  • Steven Schenker
Review Article


Liver disease in man is associated with a variety of pathophysiological processes which may influence the disposition of drugs in several ways. Interpretation of the observed pharmacokinetic changes in liver disease requires an understanding of the relationship between systemic drug clearance (Cls), volume of distribution (Vd)and the elimination half-life [t1/2(β)], i.e. t1/2(β) = 0.693· Vd/Cls.Half-life will be a measure of the fluctuation in drug level one may expect with continued administration of a drug while clearance will determine the dose required to achieve a particular steady state level. Liver disease may affect clearance and volume of distribution and so produce changes in half-life; in addition, alterations in plasma binding of drugs may occur and so influence free (unbound) drug levels. It is also possible that the end organ response, particularly in the case of sedative drugs, may be affected by liver disease.

Other factors such as age, nutrition, smoking, and concomitant drug therapy may also influence drug elimination in patients with liver disease. At the present time, caution should be exercised in prescribing drugs to patients with liver disease and the dose should be titrated to the clinical response. The development of liver function’ tests using model or marker drugs may offer some help to the prescriber in the future and enable a less empirical approach.


Morphine Liver Disease Diazepam Chronic Liver Disease Isoniazid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alvin, J.; McHorse, T.; Hoyumpa, A.; Bush, M.T. and Schenker, S.: The effect of liver disease in man on the disposition of phenobarbital. Journal of Pharmacology and Experimental Therapeutics 192: 224–235 (1975).PubMedGoogle Scholar
  2. Andreasen, P.B.; Ranek, L.; Statland, B.E. and Tygstrup, N.: Clearance of antipyrine. Dependence of quantitative liver function. Eur. J, clin. Invest 4: 129–134 (1974).Google Scholar
  3. Avant, G.R.; Schenker, S. and Alford, R.H.: The effect of cirrhosis on the disposition and elimination of clindamycin. American Journal of Digestive Diseases 20: 223–230 (1975).PubMedCrossRefGoogle Scholar
  4. Azzollini, F.; Gazzaniga, A.; Lodola, E. and Natangelo, R.: Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver. International Journal of Clinical Pharmacology 6: 1059–1065 (1972).Google Scholar
  5. Baraona, E.; Orrego, H.M.; Fernandez, O.; Amenabar, E.; Maldonado, E.; Tag, F. and Salinas, A.: Absorptive function of the small intestine in the liver cirrhosis. American Journal of Digestive Diseases 7: 318–330 (1962).PubMedCrossRefGoogle Scholar
  6. Bircher, J.; Kupfer, A.; Gikalov, I. and Preisig, R.: Aminopyrine demethylation measured by breath analysis in cirrhosis. Clinical Pharmacology and Therapeutics 20: 484–492 (1975).Google Scholar
  7. Black, M.; Mitchell, J.R.; Zimmerman, H.J.; Ishak, K.G. and Epier, G.R.: Isoniazid-associated hepatitis in 114 patients. Gastroenterology 69: 289–302 (1975).PubMedGoogle Scholar
  8. Blaschke, T.F.: Protein binding and kinetics of drugs in liver disease. Clinical Pharmacokinetics 2: 32–44 (1977).PubMedCrossRefGoogle Scholar
  9. Branch, R.A.; Herbert, C.M. and Read, A.E.: Determination of serum antipyrine half-lives in patients with liver disease. Gut 14: 569–573 (1973a).PubMedCrossRefGoogle Scholar
  10. Branch, R.A.; James, J. and Read, A.E.: The clearance of antipyrine and indocyanine green in normal subjects and in patients with liver disease. Clinical Pharmacology and Therapeutics 20: 81–89 (1976a).PubMedGoogle Scholar
  11. Branch, R.A.; James, J. and Read, A.E.: A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol. British Journal of Clinical Pharmacology 3: 243–249 (1976b)PubMedCrossRefGoogle Scholar
  12. Branch, R.A.; Morgan, M.H.; James, J. and Read, A.E.: Intravenous administration of diazepam in patients with chronic liver disease. Gut 17: 975–983 (1976c).PubMedCrossRefGoogle Scholar
  13. Branch, R.A.; Nies, A.S. and Shand, D.G.: The disposition of propranolol. VIII. General implications of the effects of liver blood flow on elimination from perfused rat liver. Drug Metabolism and Disposition 1: 687–690 (1973b).PubMedGoogle Scholar
  14. Breen, K.J.; Desmond, P.V.; Bury, R. Calder, I. and Mashford, M.L.: A l4C-phenacetin breath test in the assessment of hepatic function. Gastroenterology 72: 1033 (1977).Google Scholar
  15. Breimer, D.D.: in Pharmacokinetics of Hypnotic Drugs, pp.291–307 (Drukkerij-Vitgeverij Brakkenstein, Nijmegen 1974).Google Scholar
  16. Briant, R.H.: Dorrington, R.E.; Creal, J. and Williams, F.M.: Rate of acetaminophen metabolism in the elderly and the young. Journal of American Geriatrics Society 24: 359–361 (1976).Google Scholar
  17. Brodie, B.B.: Burns, J.J. and Weiner, M.: Metabolism of drugs in subjects with Laennec’s cirrhosis. Medicina Experimentalis 1: 290–292 (1959).PubMedGoogle Scholar
  18. Burnett, D.A.; Barak, A.J.; Tuma, D.J. and Sorrell, M.F.: Altered elimination of antipyrine in patients with acute viral hepatitis. Gut 17: 341–344 (1976).PubMedCrossRefGoogle Scholar
  19. Castleden, CM.; George, C.F.; Marcer, D. and Hallett, C: Increased sensitivity to nitrazepam in old age. British Medical Journal 1: 10–12 (1977).PubMedCrossRefGoogle Scholar
  20. Conney, A.H.; Pantuck, E.J.; Kuntzman, R.; Kappas, A.; Anderson, K.E. and Alvares, A.P.: Nutrition and chemical biotransformations in man. Clinical Pharmacology and Therapeutics 22: 707–720 (1977).PubMedGoogle Scholar
  21. Crooks, J.; O’Malley, K. and Stevenson, I.H.: Pharmacokinetics in the elderly. Clinical Pharmacokinetics 1: 280–296 (1976).PubMedCrossRefGoogle Scholar
  22. Davis, M. and Rossouw, J.E.: Drug metabolism in liver disease; in Grahame-Smith (Ed.), Drug Interactions, pp. 197–207 (University Park Press, Baltimore 1977).Google Scholar
  23. Dvorchik, B.H. and Vesell, E.S.: Pharmacokinetic interpretation of data gathered during therapeutic drug monitoring. Clinical Chemistry 22: 868–878 (1976).PubMedGoogle Scholar
  24. Farrell, G.C; Cooksley, W.G.E.; Powell, L.W. and Hart, P.: Interaction between liver disease and chronic drug ingestion on hepatic drug metabolism. Gastroenterology 71: 905 (1976).Google Scholar
  25. Fessell, J.M. and Conn, H.O.: An analysis of the causes and prevention of hepatic coma. Gastroenterology 62: 191 (1972).Google Scholar
  26. Finlayson, N.D.C; Prescott, L.F.; Adjepon-Yamoiah, K.K. and Forrest, J.A.H.: Antipyrine, lidocaine and paracetamol metabolism in chronic liver disease. Gastroenterology 67: 790 (1974).Google Scholar
  27. Hammar, C.H. and Prellwitz, W.: Die glucuronid-bildung nach perorder belastung mit acetanilid bei chronischer hepatitis und lebercirrhose. Klinische Wochenschrift 44: 1010–1014 (1966).PubMedCrossRefGoogle Scholar
  28. Hayes, M.J.; Langman, M.J.S. and Short, D.H.: Changes in drug metabolism with increasing age. 2. Phenytoin clearance and protein binding. British Journal of Clinical Pharmacology 2: 73–79 (1975).PubMedGoogle Scholar
  29. Held, H.V.; Oldershausen, H.F. and Remnier, H.: Der abban von pentobarbital bei leberschaden. Klinische Wochenschrift 48: 565–567 (1970).PubMedCrossRefGoogle Scholar
  30. Hepner, G.W. and Vesell, E.S.: Assessment of aminopyrine metabolism in man by breath analysis after oral administration of l4C-aminopyrine. New England Journal of Medicine 291: 1384–1388 (1974).PubMedCrossRefGoogle Scholar
  31. Hepner, G.W.; Vesell, E.S.; Lipton, A.; Harvey, H.A.; Wilkinson, G.R. and Schenker, S.: Disposition of aminopyrine, antipyrine, diazepam, and indocyanine green in patients with liver disease or on anticonvulsant therapy: Diazepam breath test and correlation in drug elimination. Journal of Laboratory and Clinical Medicine 90: 440–456 (1977).PubMedGoogle Scholar
  32. Hoffman, T.A.; Cestero, R. and Bullock, W.E.: Pharmacodynamics of carbenicillin in hepatic and renal failure. Annals of Inmjl Medicine 73: 173–178 (1970).Google Scholar
  33. Hvidberg, E.F.; Andreasen, P.B. and Ranek, L.: Plasma half-life of phenylbutazone in patients with impaired liver function. Clinical Pharmacology and Therapeutics 15: 171–177 (1974).PubMedGoogle Scholar
  34. Kato, R.; Oshima, T. and Tomizawa, S.: Toxicity and metabolism of drugs in relation to dietary protein. Japanese Journal of Pharmacology 18: 356–366 (1968).PubMedCrossRefGoogle Scholar
  35. Klotz, U.; Antonin, K.H. and Bieck, P.R.: Comparison of the pharmacokinetics of diazepam after single and subchronic doses. European Journal of Clinical Pharmacology 10: 121–126 (1976).PubMedCrossRefGoogle Scholar
  36. Klotz, U.; Antonin, K.H.; Brugel, H. and Bieck, P.R.: Disposition of diazepam and its major metabolite desmethyldiazepam in patients with liver disease. Clinical Pharmacology and Therapeutics 21: 430–436 (1977).PubMedGoogle Scholar
  37. Klotz, U.; Avant, G.R.; Hoyumpa, A.; Schenker, S. and Wilkinson, G.R.: The effects of age and liver disease on the disposition and elimination of diazepam in adult man. Journal of Clinical Investigation 55: 347–359 (1975).PubMedCrossRefGoogle Scholar
  38. Klotz, U.; McHorse, T.S.; Wilkinson, G.R. and Schenker, S.: The effect of cirrhosis on the disposition and elimination of meperidine in man. Clinical Pharmacology and Therapeutics 16: 667–675 (1974).PubMedGoogle Scholar
  39. Koch-Weser, J. and Sellers, E.M.: Drug therapy: Binding of drugs to serum albumin. New England Journal of Medicine 294: 311–316 (1976).PubMedCrossRefGoogle Scholar
  40. Kraus, J.W.; Marshall, J.P.; Johnson, R.; Wilkinson, G.R. and Schenker, S.: Lorazepam elimination in liver disease, Gastroenterology 73: 1228 (1977).Google Scholar
  41. Kunin, CM.; Glazko, A.J. and Finland, M.: Persistence of antibiotics in the blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. Journal of Clinical Investigation 38: 1498–1508 (1959).PubMedCrossRefGoogle Scholar
  42. Laidlaw, J.; Read, A.E. and Sherlock, S.: Morphine tolerance in hepatic cirrhosis. Gastroenterology 40: 389–396 (1961).PubMedGoogle Scholar
  43. Levi, A.J.; Sherlock, S. and Walker, D.: Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy. Lancet 1: 1275–1279 (1968).PubMedCrossRefGoogle Scholar
  44. Lewis, G.P.; Jusko, W.J.; Burke, C.W. and Graves, L.: Prednisone side effects and serum protein levels. A collaborative study. Lancet 2: 778–781 (1971).PubMedCrossRefGoogle Scholar
  45. McHorse, T.S.; Wilkinson, G.R.; Johnson, R.F. and Schenker, S.: Effect of acute renal hepatitis in man on the disposition and elimination of meperidine. Gastroenterology 68: 775–780 (1975).PubMedGoogle Scholar
  46. Marshall, J.P.; Salt, W.B. Elam, R.O.; Wilkinson, G.R. and Schenker, S.: Disposition of nafcillin in patients with cirrhosis and extrahepatic biliary obstruction. Gastroenterology 73: 1388–1392 (1977).PubMedGoogle Scholar
  47. Mawer, G.E.; Miller, N.E. and Turnberg, L.A.: Metabolism of amylobarbitone in patients with chronic liver disease. British Journal of Pharmacology 44: 549–560 (1972).PubMedCrossRefGoogle Scholar
  48. Maxwell, J.D.; Carella, M.; Parkes, J.D.; Williams, R.; Mould, G.P. and Curry, S.H.: Plasma disappearance and clinical effects of chlorpromazine in cirrhosis. Clinical Science 43: 143–151 (1972).PubMedGoogle Scholar
  49. Mehta, S.; Kalsi, H.K.; Jayaraman, S. and Mathur, V.S.: Chloramphenicol metabolism in children with protein-calorie malnutrition. American Journal of Clinical Nutrition 28: 977–981 (1975).PubMedGoogle Scholar
  50. Mitchell, J.R.; Long, M.W.; Thorgeirsson, U.P. and Jollow, DJ.: Acetylation rates and monthly liver function tests during one year of isoniazid preventative therapy. Chest 68: 181–190 (1975).PubMedCrossRefGoogle Scholar
  51. Morgan, M.H. and Read, A.E.: Antidepressants and liver disease. Gut 13: 697–701 (1972).PubMedCrossRefGoogle Scholar
  52. Murray-Lyon, I.; Young, J.; Parkes, J.D.; Knill-Jones, R.P. and Williams, R.: Clinical and electroencephalographic assessment of diazepam in liver disease. British Medical Journal 2: 265–266 (1971).CrossRefGoogle Scholar
  53. Narang, R.K.; Mehta, S. and Mathur, V.S.: Pharmacokinetic study of antipyrine in malnourished children. American Journal of Clinical Nutrition 30: 1979–1982 (1977).PubMedGoogle Scholar
  54. Nation, R.L.; Triggs, E.J. and Selig, M.: Lignocaine kinetics in cardiac patients and aged subjects. British Journal of Clinical Pharmacology 4: 439–448 (1977).PubMedCrossRefGoogle Scholar
  55. Olsen, G.D.; Bennett, W.M. and Porter, G.A.: Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clinical Pharmacology and Therapeutics 17: 677–684 (1975).PubMedGoogle Scholar
  56. Powell, L.W.P. and Axelson, E.: Corticosteroids in liver disease: Studies on the biological conversion of prednisone to prednisolone and plasma protein binding. Gut 13: 690–696 (1972).PubMedCrossRefGoogle Scholar
  57. Read, A.E.; Laidlaw, J. and McCarthy, C.F.: Effects of chlorpromazine in patients with hepatic disease. British Medical Journal 1: 497–499 (1969).CrossRefGoogle Scholar
  58. Richey, D.P. and Bender, A.D.: Pharmacokinetic consequences of aging. Annual Review of Pharmacology and Toxicology 17: 49–65 (1977).PubMedCrossRefGoogle Scholar
  59. Richter, E.; Zilly, W.; Brachtel, D. and Becker, S.: Zur frage der barbituratt-oleranz bei patienten mit akuter hepatitis. Deutsche Medizinische Wochenschrift 97: 254–255 (1972).PubMedGoogle Scholar
  60. Roberts, R.K.; Wilkinson, G.R.: Branch, R.A. and Schenker, S.: The effect of age and liver disease on the disposition and elimination of chlordiazepoxide (Librium®). Gastroenterology (In press, 1978).Google Scholar
  61. Rowland, M.; Benet, L.Z. and Graham, G.G.: Clearance concepts in pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 1: 123–136 (1973).PubMedGoogle Scholar
  62. Schalm, S.W.; Summerskill, W.H.J. and Go, V.L.W.: Prednisone for chronic active liver disease: Pharmacokinetics, including conversion to prednisolone. Gastroenterology 72: 910–913 (1977).PubMedGoogle Scholar
  63. Shideman, F.E.; Kelly, A.R.; Lee, L.E.; Lowell, V.F. and Adams, B.J.: Role of the liver in detoxication of thiopental (pentothal) in man. Anesthesiology 10: 421–428 (1949).PubMedCrossRefGoogle Scholar
  64. Shull, H.J.; Wilkinson, G.R.; Johnson, R. and Schenker, S.: Normal disposition of oxazepam in acute viral hepatitis and cirrhosis. Annals of Internal Medicine 84: 420–425 (1976).PubMedGoogle Scholar
  65. Snyder, S.H.: Opiate receptors and internal opiates. Scientific American 236: 44–56 (1977).PubMedCrossRefGoogle Scholar
  66. Squires, R.F. and Braestrup, C: Benzodiazepine receptors in rat brain. Nature 266: 732–734 (1977).PubMedCrossRefGoogle Scholar
  67. Vestal, R.E.; Norris, A.H.; Tobin, J.D.; Cohen, B.H.; Shock, N.W. and Andres, R.: Antipyrine metabolism in man: Influence of age, alcohol, caffeine and smoking. Clinical Pharmacology and Therapeutics 18: 425–432 (1975).PubMedGoogle Scholar
  68. Weiner, M.; Chenkin, T. and Burns, J.J.: Observations on metabolic transformation and effects of phenylbutazone in subjects with hepatic disease. American Journal of Medical Science 228: 36–39 (1954).CrossRefGoogle Scholar
  69. Wilkinson, G.R.: Pharmacokinetics in disease states modifying body perfusion; in Benet (Ed), The Effect of Disease States on Drug Pharmacokinetics, pp. 13–32 (American Pharmaceutical Association, Washington 1976).Google Scholar
  70. Wilkinson, G.R. and Schenker, S.: Drug disposition and liver disease. Drug Metabolism Reviews 4: 139–175 (1975).PubMedCrossRefGoogle Scholar
  71. Wilkinson, G.R. and Shand, D.G.: A physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics 18: 377–390 (1975).PubMedGoogle Scholar
  72. Williams, R.L.; Blaschke, T.F.; Meffin, P.J.; Melmon, K.L. and Rowland, M.: The influence of acute viral hepatitis on lidocaine disposition in man. Clinical Research 23: 226A (1975).Google Scholar
  73. Williams, R.L.; Blaschke, T.F.; Meffin, P.J.; Melmon, K.L. and Rowland, M.: Influence of acute viral hepatitis on the disposition of two compound with high hepatic clearance: Lignocaine and indocyanine green. Clinical Pharmacology and Therapeutics 20: 290–299 (1976).PubMedGoogle Scholar
  74. Zimmerman, HJ.: Drug-induced liver disease. Drugs 16: 25–45 (1978).PubMedCrossRefGoogle Scholar

Copyright information

© ADIS Press Australasia Pty Ltd 1979

Authors and Affiliations

  • R. K. Roberts
    • 1
  • P. V. Desmond
    • 1
  • Steven Schenker
    • 1
  1. 1.Departments of MedicineVanderbilt University School of Medicine and Veterans Administration HospitalNashvilleUSA

Personalised recommendations